ADDITIONAL FILE 4: PRISMA-P Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015 **4**:1

Section/topic	#	Checklist item	Information reported		Line number(s)					
			Yes	No	Line number(s)					
ADMINISTRATIVE INFORMATION										
Title										
Identification	1a	Identify the report as a protocol of a systematic review			1					
Update	1b	If the protocol is for an update of a previous systematic review, identify as such			N/A					
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract			49-51					
Authors										
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			5-26					
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			383-388					
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments			397-400					
		Support								
Sources	5a	Indicate sources of financial or other support for the review	\boxtimes		393-396					
Sponsor	5b	Provide name for the review funder and/or sponsor			376-377					
Role of Sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol			393-396					
INTRODUCTION										
Rationale	6	Describe the rationale for the review in the context of what is already known			79-109					
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)			118-123					



		METHODS		
Eligibility criteria	8	Specify study characteristics (e.g., PICO, study design, setting, time frame); report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility	\boxtimes	125-191
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	\boxtimes	192-198
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated		199-210
		STUDY RECORDS		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	\boxtimes	212-221
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)		222-236
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	\boxtimes	237-247
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications		248-262
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale		263-275
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether done at outcome, study level, or both; state how this information will be used in data synthesis	\boxtimes	276-288
		DATA		
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	\boxtimes	289-296
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)	\boxtimes	296-305
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)		310-325
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned		289-296 306-309
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	\boxtimes	326-333
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	\boxtimes	334-339

